CUMBERLAND PHARMACEUTICALS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CUMBERLAND PHARMACEUTICALS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $9.12M | Mar 13, 2023 |
| FY2022 | Sep 30, 2022 | $11.41M | Mar 13, 2023 |
| FY2022 | Jun 30, 2022 | $10.30M | Mar 13, 2023 |
| FY2022 | Mar 31, 2022 | $11.18M | Mar 13, 2023 |
| FY2022 | Dec 31, 2021 | $8.32M | Mar 13, 2023 |
| FY2022 | Sep 30, 2021 | $8.07M | Mar 13, 2023 |
| FY2022 | Jun 30, 2021 | $9.06M | Mar 13, 2023 |
| FY2022 | Mar 31, 2021 | $10.54M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $10.26M | Mar 11, 2022 |
| FY2021 | Sep 30, 2020 | $9.25M | Mar 11, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.68M | Mar 9, 2026 |
| FY2025 | Sep 30, 2025 | $8.29M | Mar 9, 2026 |
| FY2025 | Jun 30, 2025 | $10.84M | Mar 9, 2026 |
| FY2025 | Mar 31, 2025 | $11.71M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $10.44M | Mar 9, 2026 |
| FY2025 | Sep 30, 2024 | $9.09M | Mar 9, 2026 |
| FY2025 | Jun 30, 2024 | $9.85M | Mar 9, 2026 |
| FY2025 | Mar 31, 2024 | $8.50M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $9.35M | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | $10.09M | Mar 7, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $11.65M | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $11.20M | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $8.67M | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | $9.64M | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $9.08M | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $8.79M | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $7.41M | Mar 9, 2018 |
| FY2017 | Mar 31, 2016 | $7.74M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $8.04M | Mar 13, 2017 |
| FY2016 | Sep 30, 2015 | $7.89M | Mar 13, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.41M) | Mar 9, 2026 |
| FY2025 | Sep 30, 2025 | ($1.94M) | Mar 9, 2026 |
| FY2025 | Jun 30, 2025 | ($740.7K) | Mar 9, 2026 |
| FY2025 | Mar 31, 2025 | $1.26M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($1.90M) | Mar 9, 2026 |
| FY2025 | Sep 30, 2024 | ($1.54M) | Mar 9, 2026 |
| FY2025 | Jun 30, 2024 | ($1.09M) | Mar 9, 2026 |
| FY2025 | Mar 31, 2024 | ($1.95M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($6.29M) | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | ($1.05M) | Mar 7, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.37M) | Mar 9, 2026 |
| FY2025 | Sep 30, 2025 | ($1.97M) | Mar 9, 2026 |
| FY2025 | Jun 30, 2025 | ($747.5K) | Mar 9, 2026 |
| FY2025 | Mar 31, 2025 | $1.29M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($1.84M) | Mar 9, 2026 |
| FY2025 | Sep 30, 2024 | ($1.69M) | Mar 9, 2026 |
| FY2025 | Jun 30, 2024 | ($1.03M) | Mar 9, 2026 |
| FY2025 | Mar 31, 2024 | ($1.87M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($6.18M) | Mar 7, 2025 |
| FY2024 | Sep 30, 2023 | ($1.87M) | Mar 7, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.57M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $4.82M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $5.83M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $6.69M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $5.68M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $5.77M | Mar 11, 2022 |
| FY2021 | Dec 31, 2019 | $6.87M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $7.58M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $4.28M | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $3.19M | Mar 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.93M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($612.2K) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $6.09M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $8.45M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $6.34M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $5.42M | Mar 11, 2022 |
| FY2021 | Dec 31, 2019 | $3.06M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $3.11M | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | ($557.7K) | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $569.5K | Mar 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.9K | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $66.5K | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $281.3K | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $102.1K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $103.5K | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $140.8K | Mar 11, 2022 |
| FY2021 | Dec 31, 2019 | $246.2K | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $455.6K | Mar 12, 2021 |
| FY2019 | Dec 31, 2017 | $276.0K | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $130.9K | Mar 12, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.82M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $75.58M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $81.78M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $92.93M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $84.46M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $96.46M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $104.55M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $112.69M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $93.23M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $93.40M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.28M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $53.04M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $52.52M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $56.95M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $41.86M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $49.59M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $53.46M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $57.12M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $29.31M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $20.28M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.88M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $22.85M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $29.60M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $36.27M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $42.81M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $46.99M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $51.12M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $55.84M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $64.12M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $73.25M | Mar 9, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $914.0K | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $914.0K | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $914.0K | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $914.0K | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $882.0K | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $882.0K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $882.0K | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $784.0K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.80M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($23.97M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($17.49M) | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | ($11.21M) | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | ($5.64M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($2.13M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.21M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $4.75M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $11.71M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $18.60M | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.44M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $17.96M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $18.32M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | $19.76M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | $27.04M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $24.75M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $28.21M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | $27.94M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $45.41M | Mar 12, 2019 |
| FY2018 | Dec 31, 2016 | $34.51M | Mar 12, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 7, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 7, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 7, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Mar 13, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2024 | 0 | Mar 7, 2025 |
| FY2024 | Sep 30, 2024 | 0 | Mar 7, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 7, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 7, 2025 |
| FY2023 | Dec 31, 2023 | 0 | Mar 13, 2024 |
| FY2023 | Sep 30, 2023 | 0 | Mar 13, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14.96M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 13.95M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 14.12M | Mar 7, 2025 |
| FY2023 | Dec 31, 2022 | 14.37M | Mar 13, 2024 |
| FY2022 | Dec 31, 2021 | 14.74M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | 14.99M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 15.26M | Mar 12, 2021 |
| FY2019 | Dec 31, 2018 | 15.48M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | 16.07M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 16.07M | Mar 9, 2018 |